Literature DB >> 4020876

Essential contribution of thrombocytes to the occurrence of catecholamine-induced cardiac necroses.

H Kammermeier, M Ober.   

Abstract

The role of thrombocytes in the production of isoproterenol-induced cardiac necrosis was investigated in rats rendered thrombocytopenic (A) as well as in rats treated with a prostacyclin analogue (B). According to quantitative morphometric evaluation the area of necrotic tissue amounted to about 1% 9 h following administration of isoproterenol (40 mg/kg). In both groups of treated animals the number and area of necroses were strongly reduced (to 23% group A, to 34% group B, P less than or equal to 0.1 for both groups). In contrast, the reduction of myocardial adenine nucleotide levels induced by isoproterenol was the same (5.06 to 3.57 and 3.60 microM/g wet wt, respectively) in thrombocytopenic and non-thrombocytopenic rats. Quantitative comparison of the fraction of necrotic tissue and of the fraction of lost nucleotides suggests that non-necrotic rather than necrotic tissue predominantly contributes to the reduction of nucleotides. The dependence of cardiac necrosis production on the presence or normal aggregability of platelets points out at platelet-dependent microvascular alterations as a main cause of isoproterenol-induced cardiac necroses.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4020876     DOI: 10.1016/s0022-2828(85)80136-x

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  2 in total

1.  Catecholamine-induced cardiac necroses: protective effect of leucocytopenia, influence of an S2 antagonist, thromboxanesynthetase inhibitor and prostacycline analogue.

Authors:  L Classen; G Michalsky; H Kammermeier
Journal:  Basic Res Cardiol       Date:  1993 Jan-Feb       Impact factor: 17.165

Review 2.  Catecholamine cardiomyopathy: review and analysis of pathogenetic mechanisms.

Authors:  J P Jiang; S E Downing
Journal:  Yale J Biol Med       Date:  1990 Nov-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.